Fig. 5

Late therapeutic ibrutinib treatment in Biozzi EAE reduces spinal cord demyelination and inflammation. Analyses were performed on n = 12 representative mice/group from the experiment shown in Fig. 4a. The figure legend in c applies to all graphs. a, b Illustrative thoracic spinal cord sections stained with anti-MBP antibody (brown) and hematoxylin (nuclei; blue). Scale bars, 100 µm. c Mean demyelination scores per section, per mouse. d, e Illustrative thoracic spinal cord sections stained with hematoxylin (nuclei; blue) and eosin (cytoplasm; pink). Scale bars, 100 µm. f Mean inflammation quantified as number of 20+ cell foci per section, per mouse. g, h Magnified white matter regions from d and e demonstrating inflammatory infiltrates. No apoptotic nuclei with karyorrhexis were identified (for an example of an apoptotic nucleus, see Fig. 3i). Scale bars, 10 µm. i Mean numbers of apoptotic nuclei quantified per section, per mouse. Data in c, f, and i were obtained by taking the mean value of 3 spinal cord regions (cervical, thoracic, and lumbar) from 1 slide per stain, per mouse. Graphed data are shown as mean ± SEM. Significance was tested using a two-tailed Mann–Whitney test (c) or unpaired two-tailed t test (f, i). *p < 0.050, ***p < 0.001